Letrozole (Femara)

Letrozole competitively and reversibly binds to the heme group of the aromatase enzyme (CYP19A1) with extremely high affinity — approximately 170 times more potent than aminoglutethimide and 2-5 times more potent than anastrozole. By occupying the active site, it prevents the aromatization of androgens to estrogens. At 2.5mg/day (clinical dose), it suppresses whole-body aromatization by 97-99% and plasma estradiol to nearly undetectable levels. Because the binding is reversible, estrogen rebound occurs when the drug is discontinued — potentially more severely than with anastrozole due to the greater suppression.

Oral bioavailability is approximately 99.9%. Rapidly absorbed with peak plasma levels in 1-2 hours. Minimally protein-bound (60%). Metabolized hepatically via CYP3A4 and CYP2A6 to an inactive carbinol metabolite. Terminal half-life of approximately 2-4 days. Reaches steady state in 2-6 weeks at constant dosing, but at bodybuilding doses (intermittent, lower), functional steady state is reached faster. Excreted primarily in urine.

• ✓Most potent AI available — can control estrogen in situations where anastrozole fails
• ✓Effective emergency treatment for rapidly developing gynecomastia
• ✓Can reduce estradiol by 97-99% at clinical doses
• ✓Useful for high-aromatizing cycles with multiple wet compounds (Test + Dbol + Deca)
• ✓Achieves the driest, hardest look for pre-contest preparation
• ✓Can rescue gyno situations that are beyond SERM-only management
• ✓Long half-life supports infrequent dosing at maintenance levels

• ⚠Extremely easy to crash estrogen — crashed E2 symptoms are debilitating
• ⚠Severe joint pain and dryness from aggressive estrogen suppression
• ⚠Worst lipid impact of all three AIs — significant HDL reduction (up to 50%)
• ⚠Mood disturbances: depression, anxiety, emotional flatness
• ⚠Zero libido and erectile dysfunction when estrogen crashes
• ⚠Fatigue, brain fog, and lethargy
• ⚠Bone mineral density loss with any extended use
• ⚠Estrogen rebound upon discontinuation can be severe — must taper
• ⚠Hot flashes
• ⚠Hair dryness and thinning
• ⚠Night sweats
• ⚠Insomnia

Contraindications

• 🚫Already low estrogen levels — letrozole will crash E2 to undetectable
• 🚫Osteoporosis or low bone mineral density
• 🚫Cardiovascular disease or poor lipid profile
• 🚫Severe hepatic impairment
• 🚫As routine on-cycle AI for moderate-dose cycles — letrozole is overkill for 500mg/week test
• 🚫During PCT — absolutely not; will destroy recovery
• 🚫Hypersensitivity to letrozole

Letrozole should NEVER be used during PCT. Its extreme potency will suppress estrogen to levels incompatible with HPTA recovery. Even more than anastrozole, letrozole during PCT will prevent LH and testosterone restoration. Discontinue all letrozole before starting PCT and allow E2 to normalize.

• 1.Letrozole is NOT a first-line AI — only use it when anastrozole or exemestane are insufficient. Most users on standard testosterone cycles will never need letrozole
• 2.If you are using letrozole, you are either running very heavy aromatizing compounds or treating an emergency. Reassess your approach if you need it routinely
• 3.The 2.5mg tablet is a CLINICAL BREAST CANCER dose — bodybuilders should use 0.25-0.5mg at most for routine estrogen control
• 4.A pill cutter and careful quartering of tablets is necessary. Better yet, use a liquid formulation for accurate micro-dosing
• 5.NEVER start letrozole during PCT. If you need to lower E2 before PCT, do it 2-3 weeks prior and taper off before SERMs start
• 6.The estrogen rebound when stopping letrozole can be dramatic — always taper down (0.5mg EOD → 0.25mg EOD → 0.25mg twice weekly → stop)
• 7.If you crash your estrogen with letrozole, it takes 3-7 days to recover — eat foods with phytoestrogens (soy) and wait it out. Some users take a small dose of Dianabol (10mg) to rapidly aromatize and bring E2 back up
• 8.Letrozole's lipid impact is severe enough that prolonged use alongside AAS creates significant cardiovascular risk — keep cycles short

1. [1]Bhatnagar AS et al. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat. 2007;105 Suppl 1:7-17.
2. [2]Buzdar AU et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer. Lancet Oncol. 2006;7(8):633-643.
3. [3]Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy. N Engl J Med. 2003;349(19):1793-1802.